Noubar Afeyan - Jun 11, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Director
Signature
Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D.
Stock symbol
MRNA
Transactions as of
Jun 11, 2024
Transactions value $
-$30,087,339
Form type
4
Date filed
6/11/2024, 07:01 PM
Previous filing
Jun 7, 2024
Next filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$24.3M -164K -2.02% $148.29 7.94M Jun 11, 2024 By Flagship Ventures Fund IV, L.P. F1, F2
transaction MRNA Common Stock Sale -$4.68M -31.5K -2.02% $148.29 1.53M Jun 11, 2024 By Flagship Ventures Fund IV-Rx, L.P. F1, F3
transaction MRNA Common Stock Sale -$959K -6.42K -0.08% $149.40 7.93M Jun 11, 2024 By Flagship Ventures Fund IV, L.P. F2, F4
transaction MRNA Common Stock Sale -$184K -1.23K -0.08% $149.40 1.53M Jun 11, 2024 By Flagship Ventures Fund IV-Rx, L.P. F3, F4
holding MRNA Common Stock 3.92K Jun 11, 2024 By Flagship Pioneering, Inc. F5
holding MRNA Common Stock 1.95M Jun 11, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The shares are held directly by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3 The shares are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.755, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.